CASPS

Disease site: Other Cancers

Treatment Modality: Other

Status: Open to recruitment

Cediranib is a new, unlicensed drug that has been studied in the laboratory and clinic, which researchers think could slow the spread of alveolar soft part sarcoma (ASPS). CASPS forms part of the AstraZeneca/National Cancer Research Network Investigator-Sponsored Study Collaboration, and is investigating cediranib in the treatment of ASPS. 

CASPS is currently open to recruitment in the UK, and international participation from Australia, Spain, France and Italy is planned. 

Thirty six patients will be recruited. Patients will be randomised to 24 weeks of blinded cediranib or placebo, after which treatment will be unblinded and all patients offered open-label cediranib until objective disease progression.

Chief Investigator: Professor Ian Judson, The Institute of Cancer Research

Sponsor: The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust

Source of Funding: Cancer Research UK: CRUK/10/021 and AstraZeneca

ISRCTN: 63733470

Trial Office Contact: 
Sarah Kernaghan - Trial Manager
Phone: 020 8722 4152  |   Email casps-icrctsu@icr.ac.uk

Further information on the CASPS trial may be found on the following sites:
Current recruitment level at the UKCRN Portfolio
Patient Friendly Information at CancerHelp UK